Impact Report 2026 Creating Moments that For Patients, for Science, for Society
Note The 2026 financial year is from 1 July 2025 – 30 June 2026. All financial figures are reported in USD unless otherwise indicated. Disclaimer This Impact Report is produced by CSL Limited (ACN 051 588 348) for general information purposes only. While effort has been made to ensure the accuracy and completeness of the information at the time of publication, CSL makes no representations or warranties of any kind, express or implied, about the content’s accuracy, reliability, or suitability. Certain figures in this report are estimates or have been rounded and are indicative only. Financial figures are drawn from CSL's FY26 results and are reported in USD unless otherwise indicated. All content is the property of CSL or its licensors and is protected by applicable intellectual property laws. Reproduction is permitted only for personal, non-commercial use and must retain all proprietary notices. Some statements about products, registered product indications or procedures may differ in certain countries. Therefore, always consult the country-specific product information, package leaflets or instructions for use. For more information, please contact a local CSL representative. Brand names designated by a ® or a ™ throughout this publication are trademarks either owned by and/or licensed to CSL or its affiliates. Not all brands mentioned are used or registered as trademarks in all countries served by CSL. 2 | CSL IMPACT REPORT 2026 Our Contents 03 Introduction About CSL 09For Patients Putting Patients First, Together 21 For Science Advancing Science and Innovation 27 For Society Strengthening Health Systems and Communities 35 Looking Ahead Reflecting on the Future
about As a global biopharma company working to deliver enduring impact for patients and public health, we are always innovating to develop medicines that protect, improve and save lives around the world. Throughout our 110-year history, we've delivered many defining moments in Australian and global medical science. This includes producing Australia's first insulin, pioneering plasma fractionation, developing novel therapies for rare and serious diseases, expanding global influenza pandemic preparedness and advancing treatments that improve the lives of millions of people worldwide. Each breakthrough moment builds on the last, creating the expertise, scientific capability and global partnerships that position CSL to deliver the next generation of medical innovation and patient impact. CSL IMPACT REPORT 2026 | 3 CSL
| Introduction | For Patients | For Science | For Society | Looking Ahead AUSTRALIA CUT OFF FROM MEDICINES SUPPLY World War I shows Australia can no longer rely on overseas sources for lifesaving medicines. As a result, the Commonwealth Government announces it will establish a federal serum institute 'for preparations of vaccines, serums and anti-toxins'. 1915 SNAKEBITE BREAKTHROUGH After several years of research collaboration, CSL releases an antivenom against the deadly tiger snake. It goes on to develop antivenoms for Australia's most venomous creatures. 1930 THE CSL JOURNEY BEGINS Dr William Penfold, a renowned bacteriologist in Britain, is appointed as the founding Director of the Commonwealth Serum Laboratories. On 25 April, his first day of work, he lets people know that his new organisation would 'live or die by the quality of its products'. 1916 TREATING SHOCK ON THE BATTLEFIELD Close collaboration with Harvard's Dr. Edwin Cohn sees Chicago-based Armour Laboratories become the largest supplier of human albumin to the U.S. military during WWII, providing a vital treatment for blood loss and shock. 1940 FIRST BIG TEST The Spanish flu pandemic, which killed at least 50 million people globally, strikes Australia. CSL rapidly produces 3 million doses of a mixed bacterial vaccine that combats the complications of the disease. 1919 FIGHTING THE FLU VIRUS CSL starts production of influenza virus vaccine, supplying 1 million doses to Australian and British troops. The egg-based method used is based on the pioneering work of Australian scientist Macfarlane Burnet. 1944 DIABETES RELIEF Soon after the Canadian discovery of insulin, CSL becomes one of only four laboratories in the world licensed to make it. Within months, CSL is producing enough insulin to meet the needs of all Australians. 1923 PENICILLIN PRODUCTION Acting on international advancements made by Howard Florey, CSL starts large-scale production of penicillin. Production enables Australia to become the first country in the world to provide penicillin to its civilians. 1944 Creating Moments that 4 | CSL IMPACT REPORT 2026
CSL IMPACT REPORT 2026 | 5 POLIO TRIUMPH Just a few short months after Salk's breakthrough in the U.S., CSL issues its first batches of polio vaccine. As a result of vaccination, polio is virtually eliminated in Australia within a number of years. 1956 CSL GOES PUBLIC CSL debuts on the Australian Stock Exchange as a public company. 1994 A FIRST FOR FLU Seqirus successfully commercialises the manufacturing process at its Holly Springs U.S. facility and launches the world’s first four-strain, cell culturederived influenza vaccine. 2016 HAEMOPHILIA HELP CSL issues its first clotting factor treatment for haemophilia A patients in Australia. It also commences plasma fractionation for New Zealand, followed later by Hong Kong, Malaysia, Singapore and Taiwan. 1961 FIRST HPV VACCINE WINS APPROVAL The FDA approves the world's first HPV vaccine for the prevention of cervical cancer and genital warts. It is subsequently launched in major markets around the world, vastly reducing the burden of HPV-related disease. 2006 RECOMBINANT SUCCESS CSL’s first novel recombinant therapies to treat haemophilia are approved in the U.S. 2016 TECHNICAL EXPERTISE IN FLU CSL begins to adapt (re-assort) influenza strains so they grow better in eggs. The resulting 'manufacturing seeds' are provided to the WHO each season, who in turn shares them with all manufacturers for vaccine production. 1973 NEXT GENERATION IVIG CSL Behring launches the first liquid intravenous immunoglobulin able to be stored at room temperature. It quickly becomes CSL Behring's leading product globally. 2007 CELL THERAPY CSL launches its first cell and gene therapy product, which offers patients previously unheard of potential for a functional cure for haemophilia B. 2022 PROTECTING NEWBORNS In a world first, CSL issues Rhesus (D) immunoglobulin. Produced from plasma, it prevents haemolytic disease in newborns due to Rh factor incompatibility. 1967 NEW TREATMENT APPROVED FOR HAE The FDA approves the first treatment in the U.S. for acute abdominal or facial attacks associated with hereditary angioedema (HAE), a rare and serious genetic disorder. It also achieves approval in 20 European countries and the label later expands to include self-administration. 2009 FIRST IN CLASS A first-in-class monoclonal antibody is launched globally offering convenient monthly prophylactic dosing to prevent hereditary angioedema (HAE) attacks. 2025 Q FEVER VACCINE FIRST Based on the work of Professor Barrie Marmion, CSL launches a Q fever vaccine. It becomes a product of national significance in Australia, protecting people who work with livestock. It remains the only vaccine of its kind available. 1988-89 PLASMA CENTRE OF THE FUTURE CSL Plasma opens its first Centre of the Future in Kansas City, Missouri, U.S. The result of three years of design and development work, the model provides a blueprint for enhancing the donor experience and improving operational efficiencies. 2010
This Impact Report highlights our work in financial year 2026 (FY26) to create lifesaving medicines, safeguard public health, advance science and contribute positively to the communities where we live and work. Our $12.1m contributed to science and innovation to advance knowledge, research and careers in biomedicine. 114m doses of seasonal influenza vaccine distributed globally. 41 clinical trials in operation across all therapeutic areas. $28m contributed to support patient communities. ~$6m in economic activity per donor centre. $2.1m in contributions to local communities. 83 major regulatory approvals. 6 | CSL IMPACT REPORT 2026 ~8.3m patients treated with plasmaderived and recombinant therapies. 120+ countries make use of CSL’s lifesaving vaccines and medicines | Introduction | For Patients | For Science | For Society | Looking Ahead
This year marks 110 years since CSL was founded with a simple purpose: to improve and protect human health. What began in 1916 as a small Australian laboratory has grown into a global biopharma company serving millions of people around the world. Over the past century, our purpose has remained constant. What drives us? Our commitment to patients and public health, our passion for scientific innovation and our determination to deliver high-quality medicines that save and improve lives. Today, CSL reaches millions of patients through world-class medicines across our five therapeutic areas – haematology, immunoglobulins, cardiovascular and renal, immunology and vaccines. For decades, our success has been built upon understanding patients’ needs, underpinned by excellent science, deep expertise and people who genuinely care about the patients and communities we serve. Each year, we measure our impact through facts and figures. While these numbers tell an important story, the people behind them matter most. Our medicines reached thousands of people living with rare diseases. Millions more relied on them at critical moments, whether welcoming a child or facing a medical emergency. As we look to the future, we remain focused on the purpose that has always guided CSL: delivering sustainable, improved outcomes for patients and public health. This report highlights the moments that mattered over the past year – for patients, for science and for society. Gordon Naylor Interim Chief Executive Officer & Managing Director From our CSL IMPACT REPORT 2026 | 7 | Introduction | For Patients | For Science | For Society | Looking Forward CEO
Our Impact Framework Our purpose and values guide how we seek to create impact. They shape where we invest our time, resources and expertise, ensuring our activities support our mission while reflecting the principles that define how we work. 8 | CSL IMPACT REPORT 2026 | Introduction | For Patients | For Science | For Society | For People | Looking Ahead Deliver enduring impact for patients and public health Our Values Our Values turn purpose into action. They guide how we innovate, collaborate and make decisions every day, enabling us to create enduring value for patients, communities, employees, partners and shareholders alike. Integrity Innovation Superior Performance Collaboration Patient Focus Our Purpose We combine science, innovation and expertise to address unmet medical needs and deliver lasting impact for patients worldwide.
Putting Patients First, together We develop innovative medicines that seek to provide sustainable improvements in patient outcomes. Through innovation and responsible access, we aim to improve the health and quality of life of people all around the world. CSL IMPACT REPORT 2026 | 9
| Introduction | For Patients | For Science | For Society | Looking Ahead Delivering on a Scale Today, CSL provides a diverse portfolio of lifesaving medicines and vaccines to patients in more than 120 countries worldwide. ~6.6k people living with haemophilia A & B ~1.3m pregnant women with rhesus incompatibility ~9.0k people living with protein deficiencies (including hereditary angioedema (HAE), alpha-1 antitrypsin deficiency (AATD)) ~4.1m people whose health was threatened by sepsis, cirrhosis, hypoalbuminaemia and a range of other conditions $22.3m supporting product access around the world ~167k people living with autoimmune diseases and immune deficiencies In FY26, our medicines were used in the treatment of: 10 | CSL IMPACT REPORT 2026
Spanning five therapeutic areas: We deliver our portfolio of lifesaving medicines through our three businesses: Legend Countries where CSL provides medicines and vaccines Countries where CSL does not currently provide medicines and vaccines Map reflects countries where CSL products are registered or supplied as of September 2026.or supplied as at September 2026. CSL Behring Leading the way in treating rare and serious diseases CSL Behring discovers, develops and delivers innovative therapies for people living with a range of rare and serious health conditions. CSL Seqirus Securing health for all of us CSL Seqirus is a leader in the prevention of influenza globally and a transcontinental partner in pandemic preparedness. CSL Vifor Changing the game in iron deficiency and nephrology CSL Vifor is a global leader in therapies for iron deficiency and nephrology. CSL IMPACT REPORT 2026 | 11
| Introduction | For Patients | For Science | For Society | Looking Ahead From Donated Plasma to Lifesaving Therapies Plasma-derived therapies are made from human plasma generously donated by people around the world. These medicines are used to treat rare and serious conditions, including immune deficiencies, bleeding disorders, neurological diseases and hereditary angioedema. What is plasma and how is it used as a medical treatment? • Plasma is a straw-coloured liquid that carries red blood cells, white blood cells and platelets. • It’s made up of water (~90%), proteins and clotting factors (8%), as well as small amounts of salts, glucose (blood sugar) and lipids (fats). • Plasma circulates in our blood, helping maintain blood pressure and delivering proteins that support blood clotting and fight disease. • Plasma-derived therapies help treat medical conditions where a particular protein usually found in a person’s plasma is missing or deficient. • Plasma-derived albumin helps to restore circulating blood volume in emergency and critical care situations, including for patients with severe burns, trauma, sepsis and major blood loss. Fact Stacy’s Story Stacy lives in Arizona, U.S. She’s a former nurse, devoted mum and outdoor enthusiast who enjoys travelling, spending time with family and friends and making memories with her son. Stacy lives with two primary immunodeficiency conditions. Primary immunodeficiencies are a group of more than 450 rare, chronic conditions in which part of the body’s immune system is missing or does not function correctly. These conditions can affect anyone, regardless of age, gender or ethnicity. Before getting the right diagnosis, Stacy lived for years with frequent infections. Today, she manages her conditions with immunoglobulin therapy made from donated plasma. Plasma-derived therapies help replace antibodies her body is missing, reducing her risk of serious infections and helping her lead an active life. Her message to plasma donors is one of sincere gratitude. “Thank you for taking the time to donate,” says Stacy. “Your generosity helps people like me live fuller, healthier lives. What may seem like a small act can make a life-changing difference for patients who depend on plasmaderived treatments.” 12 | CSL IMPACT REPORT 2026
Every Plasma Donation Matters Behind every plasma-derived therapy are thousands of plasma donations. For some rare and chronic conditions, a single patient may rely on hundreds – or even thousands – of plasma donations each year. In Australia, the Australian Red Cross Lifeblood collects plasma from donors and supplies it to CSL Behring to manufacture essential medications. Internationally, CSL Plasma operates 334 plasma donation centres across the U.S., Germany and Hungary, helping ensure a reliable supply of human plasma to manufacture lifesaving medicines for patients worldwide. Manufacturing Plasma-Derived Therapies Starts with Generous Donors By transforming a precious natural resource into innovative therapies, CSL Behring aims to help patients manage chronic conditions, prevent life-threatening complications and live healthier, more fulfilling lives. Through continued investment in plasma collection, manufacturing and scientific innovation, we are working to expand access to these essential medicines and helping meet the growing needs of patients worldwide. Our three state-of-the-art logistics centres in the U.S. and Germany are responsible for receiving, storing and shipping the plasma that is donated at our collection centres. Inventory is controlled by sophisticated logistics software linked to our donor management system. This means we have "vein to vial" control; we can trace each plasma unit from its initial donation, through to laboratory testing, logistics and fractionation – and ultimately, to the product made from the plasma donated. 130 plasma donations are needed to treat one patient with primary immunodeficiency for one year 1,200 plasma donations are needed to treat one patient with severe haemophilia for one year 900 plasma donations are needed to treat one patient with alpha-1 antitrypsin deficiency for one year 1,000 plasma donations are needed to treat one patient with hereditary angioedema for one year CSL IMPACT REPORT 2026 | 13
| Introduction | For Patients | For Science | For Society | Looking Ahead Hereditary angioedema (HAE) is a rare genetic disease that causes recurrent episodes of severe swelling in different parts of the body. These attacks are unpredictable, vary in severity and affect areas including the abdomen, face, extremities and throat. Swelling in the throat can become lifethreatening if it blocks the airway. Although HAE affects only around 1 in 50,000 people worldwide, the impact on those living with the condition can be profound. Most HAE patients (76%) said the condition disrupted their lives and limited productivity, according to four multinational surveys CSL Behring conducted across Europe (n = 479). Forty to 70% said they skipped leisure activities due to fear, anxiety or risk of attacks.* The experience of HAE differs from person to person and can change over time. Treatment needs may vary depending on an individual’s disease burden, goals, life stage and personal preferences. This reinforces the importance of access to treatment options that support more individualised care. Building on its longstanding commitment to the HAE community, CSL continues to expand treatment options for people living with the condition. Our aim is to support patients across the continuum of care, helping to both prevent and treat acute episodes. Supporting People Across the Hereditary Angioedema Care Journey HAE is one of the most difficult things I’ve faced. But with modern long-term prophylaxis, I often forget I have this unpredictable rare disease. I’m grateful that I can enjoy my retirement, travel around the world, spend time with my grandkids and embrace other activities I love that make life exciting... Julie, lives with hereditary angioedema *Source: Metcalfe, A et al., 2025. Poster Presentation, Global Angioedema Leadership Conference (GALC) 2025, Madrid, Spain. 14 | CSL IMPACT REPORT 2026
Advancing Treatment for Kidney Disease Kidney disease encompasses a range of conditions that can lead to kidney failure, dialysis or transplantation if left untreated. CSL Vifor develops and delivers targeted therapies for chronic kidney disease and rare kidney disorders. We have developed a broad range of therapies and medicines to preserve renal function, manage complications and improve patients’ quality of life with kidney disease. CSL also continues to advance research into the long-term management of chronic kidney disease. Helping Patients with IgA Nephropathy ‘Know Their Numbers’ On World Kidney Day 2026, CSL reaffirmed its commitment to supporting the kidney disease community and improving outcomes for people living with IgA nephropathy (IgAN). Central to managing IgAN is understanding the three ‘numbers’ that matter most: proteinuria, estimated glomerular filtration rate (eGFR) and blood pressure. To help patients take a more active role in managing their condition, CSL Vifor launched the Navigate Your Numbers campaign in collaboration with the U.K.’s National Kidney Federation. The campaign empowers people living with IgAN to better understand these three key measures, track changes over time and have more informed conversations with their healthcare team about disease progression. This booklet has been created by CSL Vifor in collaboration with the National Kidney Federation and people living with and treating IgA nephropathy. NAVIGATE YOUR NUMBERS in IgA nephropathy TRACKING YOUR NUMBERS: A guide of key numbers for people with IgA nephropathy UK-NP-2500178 | September 2025 Iron is an essential mineral involved in many vital functions throughout the body. When your body has the iron levels it needs, you have the foundation for energy, focus and overall wellbeing. Iron deficiency is one of the most common complications of chronic kidney disease, heart failure and inflammatory disorders. However, there are many other reasons a person may find themselves low in iron, such as inadequate dietary intake, heavy periods or poor gut absorption. It’s surprisingly common in women of reproductive age, affecting 11–35% of non-pregnant women,* yet it often slips under the radar. Treatment of iron deficiency is particularly important for relieving day-to-day symptoms such as fatigue, headaches, shortness of breath and ‘brain fog’. This year, CSL Vifor saw a need to help women better understand the prevalence of iron deficiency and why iron matters for good health. We launched a disease awareness campaign called Her Iron Matters, including the educational website herironmatters.com, to draw attention to this common health issue and encourage more women to get checked. As of August 2026, the campaign has reached 6.2 million women, garnering more than 300,000 website visits and an above- benchmark engagement rate of 32%. *Source: Burns et al., 2025 (doi.org/10.1016/j.jtemb.2025.127684) Overcoming Iron Deficiency in More Ways Than One | Introduction | For Patients | For Science | For Society | Looking Forward CSL IMPACT REPORT 2026 | 15
| Introduction | For Patients | For Science | For Society | Looking Ahead Through its long-standing partnership with the World Federation of Hemophilia (WFH) Humanitarian Aid Program, CSL Behring is supporting efforts to strengthen haemophilia communities in countries where significant gaps remain. Through engagement with patients, clinicians, patient organisations and health authorities, CSL Behring and WFH support education, advocacy and local capability. This helps communities build greater knowledge and capacity around haemophilia. Recent field visits to Morocco and Uzbekistan with WFH reinforced the importance of this approach. As CSL’s Senior Director, Head of Global Patient Advocacy and Policy, Dr Sujan Sivasubramaniyam, explains: “Humanitarian aid can be a bridge to lasting progress – providing vital support today, while partnerships help strengthen health systems and build local capability for the future.” Supporting the Next Generation of Bleeding Disorders Research For more than 40 years, the Professor Heimburger Award has recognised outstanding early-career researchers dedicated to advancing care for people with bleeding disorders. In 2025, five researchers across leading European universities and medical centres received a €25,000 EUR research grant from CSL, including Sophie Hordijk, a PhD candidate at Erasmus Medical Center in the Netherlands. Sophie’s research focuses on uncovering the biological mechanisms that drive gastrointestinal bleeding in people with von Willebrand disease. By deepening scientific understanding of this serious condition, her work aims to identify new therapeutic targets that could lead to additional treatment options. By supporting emerging researchers like Sophie, the Professor Heimburger Award helps accelerate scientific discoveries and foster innovation with the potential to improve outcomes for people with bleeding disorders worldwide. Partnering With the World Federation of Hemophilia 16 | CSL IMPACT REPORT 2026
Influenza is one of the fastest-changing vaccine-preventable diseases and has a significant impact on people and health systems across the globe. The World Health Organization (WHO) estimates that seasonal flu infects 1 billion people annually, causing severe illness in 3–5 million and 290,000–650,000 respiratory deaths.* As one of the world’s largest influenza vaccine providers, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-theart production facilities in the U.S., the U.K. and Australia, CSL Seqirus utilises egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world. 114m seasonal flu doses distributed globally 232m people protected in pandemic agreements 40k deaths prevented globally 355k hospitalisations prevented globally Advancing Public Health Protection for a Changing World | Introduction | For Patients | For Science | For Society | Looking Forward *Source: World Health Organization: www.who.int/news-room/fact-sheets/detail/influenza-(seasonal); last accessed 28 September 2026. CSL IMPACT REPORT 2026 | 17
| Introduction | For Patients | For Science | For Society | Looking Ahead From Surveillance to Vaccine Readiness Influenza pandemic preparedness begins long before an outbreak occurs. Through ongoing surveillance, scientific partnerships and investment in advanced manufacturing capabilities, CSL Seqirus monitors emerging influenza threats and maintains the expertise, infrastructure and global production network needed to respond rapidly when a novel virus emerges. This end-to-end approach, from identifying potential pandemic strains through to developing, manufacturing and supplying vaccines at scale, helps strengthen global health security and supports more equitable access to pandemic vaccines when they are needed most. Based on this foundation, CSL Seqirus continues to work with governments, public health agencies and international organisations to improve preparedness and help protect communities around the world. CSL’s new Tullamarine manufacturing facility is set to strengthen Australia’s health security and support global pandemic preparedness. The site uses advanced, scalable technology to enable year-round vaccine production and rapid response during emerging health threats. The digitally connected facility features automated, paperless manufacturing systems and advanced analytics to optimise production, quality and supply reliability. Supporting a A$300 million AUD vaccine and antivenom supply chain, the site brings together hundreds of experts to deliver influenza and other vaccines. A New Era of Vaccine Manufacturing in Australia 18 | CSL IMPACT REPORT 2026
$63.2m contributed to the World Health Organization’s Pandemic Influenza Preparedness Framework since 2012 Vaccine access, alongside surveillance and testing, is critical for pandemic preparedness and provides reassurance to governments and their populations alike. Lorna Meldrum, Vice President Commercial Operations, International & Pandemic Response, CSL Seqirus Protecting Communities Through Regional Collaboration Supporting The Next Generation of Vaccine Researchers Through its support of the European Scientific Working Group on Influenza’s Early Career Scientist Award, CSL Seqirus is helping recognise and encourage emerging researchers whose work is advancing influenza science and contributing to the development of more effective vaccines. In 2025, Dr Marios Koutsakos from the Doherty Institute, University of Melbourne, received the award for his research into how the immune system recognises influenza B viruses. His work is helping deepen understanding of immune responses and could contribute to the development of more effective influenza vaccines. By investing in emerging scientific talent and fostering collaboration between academia and industry, CSL Seqirus is helping advance the research needed to tackle one of the world's most persistent infectious diseases. In FY26, CSL Seqirus announced two landmark partnerships with the Pan American Health Organization (PAHO) to strengthen influenza prevention and pandemic preparedness across Latin America and the Caribbean. Through a long-term agreement with PAHO's Revolving Fund, CSL Seqirus will expand access to its differentiated seasonal influenza vaccine portfolio while working with long-standing partner Sinergium Biotech to localise vaccine filling and distribution in the region, helping build sustainable regional manufacturing capability and supply resilience. CSL Seqirus also signed a pioneering pandemic preparedness agreement with PAHO, reserving 14 million doses of pandemic influenza vaccine for participating member states in the event of a WHO-declared pandemic, supporting faster and more equitable access to vaccines. Partnering to Improve Equitable Access During a Pandemic Influenza pandemics do not respect borders, making equitable access to vaccines a critical component of global health security. CSL Seqirus supports pandemic preparedness through its global manufacturing network, scientific expertise and long-standing partnerships with governments, public health agencies and international organisations. A key part of this commitment is CSL Seqirus' participation in the World Health Organization's (WHO) Pandemic Influenza Preparedness (PIP) Framework. Through this unique public-private partnership, CSL Seqirus has pledged to make available 10% of its real-time pandemic influenza vaccine production to the WHO for deployment to developing countries during a declared influenza pandemic, helping strengthen global preparedness and expand access to vaccines for populations that might otherwise face barriers to timely supply. CSL IMPACT REPORT 2026 | 19
| Introduction | For Patients | For Science | For Society | Looking Ahead A Legacy of Protection – Powered by Partnership and Education Papua New Guinea (PNG) Snakebite Partnership Approximately 10% of CSL’s annual antivenom production is donated to Papua New Guinea, where snakebite continues to pose a major public health threat. 560 vials of antivenom distributed across 15 provinces in 2025 70+ health facilities supplied with lifesaving treatment 1,189 healthcare workers trained in snakebite assessment, antivenom use and patient reporting 3k+ lives saved through the partnership since it began ~25% of patients treated have been children Since the 1930s, CSL Seqirus has helped protect communities from some of Australia's most dangerous venomous animals through the manufacture of lifesaving antivenoms. At the heart of this work is a unique partnership with the Australian Reptile Park. For more than 70 years, the Park's specialist keepers have supplied snake and spider venom essential for antivenom production, enabling CSL Seqirus to transform a natural hazard into lifesaving protection. In FY26, CSL Seqirus expanded its partnership with the Australian Reptile Park through a three-year sponsorship, valued at A$210,000 AUD supporting education, awareness and training initiatives focused on venomous creatures and first aid for bites and stings. By combining public education with one of Australia's longestrunning scientific partnerships, the initiative helps strengthen community resilience and supports the broader mission of saving lives through prevention and access to lifesaving antivenoms. Together, this enduring collaboration between CSL and the Reptile Park has contributed to saving more than 25,000 lives, demonstrating the power of science, expertise and partnership to protect vulnerable communities. 20 | CSL IMPACT REPORT 2026
Advancing and Innovation Scientific innovation is the foundation of CSL's ability to deliver enduring impact. By combining worldclass science with specialised manufacturing and strategic partnerships, we continue to invest in the discoveries that will improve patient outcomes for decades to come – expanding our understanding of disease, developing new therapies and improving existing treatments for patients. Together with our researchers, partners and collaborators, we are nurturing a pipeline of future innovations and new scientific talent to help address unmet medical needs for patients around the world. science CSL IMPACT REPORT 2026 | 21
| Introduction | For Patients | For Science | For Society | Looking Ahead How Innovation Becomes Patient Impact CSL combines world-leading science, specialist manufacturing, strategic partnerships and clinical expertise to transform promising discoveries into novel therapies. By maintaining a balanced portfolio of research – both advancing existing medicines and investing in the next generation of treatments – we continue to build a pipeline designed to meet patient needs and priorities today, while preparing for the healthcare challenges of tomorrow. Priority Why It Matters Address unmet medical needs Focus on diseases where patients have limited treatment options. Advance differentiated therapies Develop medicines that combine scientific innovation with specialised manufacturing expertise. Strengthen our therapeutic leadership Build on CSL's expertise in immunology, haematology, cardiovascular and renal disease, transplantation and vaccines. Accelerate the path from discovery to patients Integrate research, partnerships, portfolio development and commercialisation. Invest in next-generation technologies Harness advanced biologics, AI and digital capabilities to improve research and manufacturing. Build innovation for the future Develop global research capability, manufacturing excellence and strategic partnerships that sustain long-term patient impact. By partnering with biotech’s brightest, we continually renew our therapeutic portfolio with the most promising scientific advances. Pairing their breakthroughs with our deep disease, operations and commercial expertise will ultimately allow accelerated development of transformative therapies for patients with rare and serious diseases. Gordon Naylor, CSL's Interim Chief Executive Officer and Managing Director Investing in the Future of Medicine clinical trials in operation across all therapeutic areas 23 new indications for existing products 60 new product registrations 83 major regulatory approvals $1.2b USD invested in R&D 41 Our Innovation Priorities 22 | CSL IMPACT REPORT 2026
The Role of Clinical Trials Every medicine must undergo rigorous clinical testing before it can be approved for use. Clinical trials are carefully designed research studies that evaluate the safety and effectiveness of new medicines in people. They are a vital step in the development process, helping researchers understand how a treatment works, determine the most appropriate dose, identify potential side effects and demonstrate whether it provides meaningful benefits for patients. Making Clinical Trial Participation Easier for Patients CSL incorporates flexible and decentralised options into clinical trial design to improve accessibility, reduce participant burden and promote equity. These options include electronic Clinical Outcome Assessments (eCOA) with Bring Your Own Device capability, eLearning, alternative locations for study procedures and telehealth visits. These features are designed to make participation easier and more inclusive, supporting improved recruitment and retention while enabling the collection of more robust and representative data. In FY26, 89% of Phase II/III studies included flexible options, which were recommended by patient advisors to reduce the burden on participants. HOW MEDICINE GETS FROM THE LABORATORY TO THE PHARMACY Trial Plan Developed and Reviewed After discovery of potential treatment, pre-clinical studies are conducted to ensure basic questions about its safety. Phase III The potential treatment is tested with an even larger group of people (1,000 – 3,000) to confirm effectiveness, monitor for side effects, compare it to commonly used treatments and collect information about safe use. Clinical Trials Begin For a treatment to be approved, it must pass a three-phase clinical trial process. Phase II The study treatment is tested with a larger group of people (100 – 300) to further evaluate safety and assess effectiveness. Results Evaluated Results of clinical trial are evaluated and submitted for review. Phase I Researchers test a new treatment with a small group of people (20 – 80) to evaluate safety, determine safe dosage range and identify side effects. Approval After a thorough review, regulatory agency may approve the new treatment for medical use. Phase IV: Post-Approval Marketing studies are conducted to gain additional insights about the treatment's risks, benefits and optimal use. | Introduction | For Patients | For Science | For Society | Looking Forward CSL IMPACT REPORT 2026 | 23
| Introduction | For Patients | For Science | For Society | Looking Ahead In 2026, CSL’s Centenary Fellowships reached the conclusion of their planned 10-year program, leaving a lasting legacy for Australian medical research. Established in CSL’s centenary year, the A$25 million AUD initiative supported 20 exceptional early- to mid-career researchers with five years of funding to pursue ambitious discovery and translational research in Australia. Over the decade, the fellowships helped researchers build independent careers, support PhD students and scientific staff, and advance research with the potential to shape future treatments. With the final fellowships now awarded, the program stands as a long-term investment in the people and ideas helping to strengthen Australia’s medical research community and drive the science of tomorrow. science Investing in Medical Dr Con Panousis BSc (Hons), PhD (Biochemistry) | Melbourne, Australia Vice President, Drug Discovery (Biomedical researcher), CSL Research “I’ve spent my career working in drug discovery because I believe in the power of science to improve lives. Today, I work in teams focused on discovering new biologic therapies for people with serious and rare diseases. While my role has evolved over time, what motivates me has remained consistent for the past 30 years – the opportunity to understand disease more deeply and translate that understanding into treatments that can genuinely help patients.” Mollie Barrett BA (Psychology) | California, USA Senior Director, Therapeutic Area Operations – Hematology, CSL Behring “The haematology area is complex and ever evolving, and it often feels like working through a puzzle. This certainly keeps the work challenging and engaging in the best way. After years of research, bringing a project to life as a clinical trial is incredibly energising. Each trial represents progress, and each milestone is one step closer to getting potential new medicines to patients.” Hanna Sundström BSc MSc PhD (Biochemistry) | Zurich, Switzerland Global Regulatory Strategy, Director, CSL Vifor “At CSL, I help guide promising new therapies through sometimes quite complicated regulatory and clinical pathways so these medicines can reach the patients who need them. I translate the science into something that health authorities can assess and ultimately approve as a new medicine for patients. I hope that the scientific community can continue to close the gap between early scientific discovery and real patient impact so that we can move even faster to create more targeted treatments for conditions that have limited options, or others where there are still no therapies. It becomes so meaningful when we remember why we do this.” 24 | CSL IMPACT REPORT 2026
Plasma Fractionation Facility Wins Global Pharmaceutical Engineering Award CSL Behring's state-of-the-art plasma fractionation facility in Broadmeadows, Victoria, was named 2025 Facility of the Year in the Pharma 4.0 category by the International Society for Pharmaceutical Engineering, recognising its advanced use of digital technologies and automation. Now fully operational, the facility is the largest of its kind globally, increasing CSL Behring's Australian plasma processing capacity ninefold to more than 10 million litres of plasma each year. A digital twin, advanced robotics and an automated warehouse help improve safety, efficiency and flexibility, while the facility's modular design allows it to adapt as needs evolve. The investment strengthens Australia's biopharmaceutical manufacturing capability while supporting CSL Behring's ability to turn donated plasma into lifesaving medicines for patients around the world. Advancing Sustainable Science Through My Green Lab Innovation isn't only about what we discover, but how we do it. In FY26, CSL’s Level 7 laboratories in Melbourne, Australia, became the first CSL laboratories globally to achieve My Green Lab® Silver certification, recognising practical changes that reduce the environmental impact of scientific research. From improving freezer management to reducing unnecessary energy use and embedding more sustainable laboratory practices, the initiative demonstrates how small changes across day-to-day research can make a meaningful difference. Led by the CSL Melbourne Laboratory Green Team, the achievement is a first step towards building a stronger culture of sustainable science across CSL. By making laboratories more efficient and reducing their environmental footprint, CSL is helping ensure that the science driving future medicines is also supporting a more sustainable future. CSL laboratories based in the U.S. (Waltham) and U.K. (Liverpool)) are also progressing towards My Green Lab certification through CSL's pilot program. CSL IMPACT REPORT 2026 | 25
| Introduction | For Patients | For Science | For Society | Looking Ahead Building the Next Generation of Manufacturing and Scientific Talent CSL is investing in the next generation of scientific and technical talent. Our apprentices in Switzerland learn advanced manufacturing trades. In Australia and the U.S., graduates and interns contribute to engineering, manufacturing, information & technology and research programs. Our education partnerships help nurture and develop future scientists, researchers and innovators. We're proud to support young people inspired to pursue careers in science, technology, engineering and math (STEM). Inspiring the next generation through STEM In FY26, CSL renewed its long-standing partnership with the National Youth Science Forum (NYSF) in Australia, reaffirming its commitment to inspiring future scientists and strengthening the country's STEM pipeline. As a four-year Gold Partner, CSL will continue supporting the NYSF Year 12 Program and other outreach initiatives, with CSL scientists sharing their expertise, career experiences and insights into the opportunities available in biotechnology and pharmaceutical research. As NYSF CEO Dr Melanie Bagg noted, CSL's scientists bring invaluable real-world experience that helps students explore meaningful careers in science and biotechnology. CSL is also supporting future scientific talent in Germany through the national German Scholarship Program (Deutschlandstipendium). In 2026, CSL Behring funded scholarships at universities in Marburg, Freiburg and the Technische Hochschule Mittelhessen (THM) in Gießen, helping talented students pursue their studies while strengthening connections between academia and industry. In the U.K., CSL Seqirus is creating earlier pathways into STEM through its partnership with Tutors United, which established the first CSL Seqirus-funded STEM Hub at St. Christopher's Catholic Primary School in Liverpool. By strengthening foundational skills and expanding educational opportunities, these initiatives reflect CSL's belief that investing in education today helps build the scientific workforce that will drive the medical breakthroughs of tomorrow. From apprentices to future innovators CSL Behring has invested significantly in developing vocational talent at its manufacturing site in Bern, Switzerland, with a well-established apprenticeship system. Current pathways include Automation Engineer, Polymechanic (precision engineering), Plant Operator (pharmaceutical manufacturing), Biology Laboratory Assistant, Chemistry Laboratory Assistant and Logistics Officer. These formal multi-year apprenticeships combine classroom education with practical experience in a Goods Manufacturing Practice (GMP) pharmaceutical manufacturing environment. Part of CSL's Promising Futures early careers strategy, the program helps school leavers develop technical skills while contributing to medicines manufacturing and quality control. The program now also includes an exchange element, enabling apprentices from CSL’s Broadmeadows manufacturing site in Victoria, Australia, to spend time at the Bern facility and vice versa. 26 | CSL IMPACT REPORT 2026
Strengthening Health Systems and Creating lasting health impact extends beyond the medicines we develop. CSL works with healthcare professionals, patient organisations, governments and community partners to strengthen health systems, improve access to care and support better outcomes for patients around the world. By investing in education, advocacy, public health initiatives and community partnerships, we help build more resilient healthcare systems and healthier communities. Together, these efforts complement our scientific innovation and enable us to create broader, long-term impact for the people and communities we serve. communities CSL IMPACT REPORT 2026 | 27
| Introduction | For Patients | For Science | For Society | Looking Ahead Every CSL Plasma donor centre helps strengthen the local communities we serve. With over 300 plasma centres across the U.S., Germany and Hungary, each centre generates approximately $6 million USD in annual economic activity – supporting local jobs, wages, donor payments and nearby businesses (e.g., janitorial, waste management, alarm monitoring, landscape, maintenance, etc.). In the U.S. alone, a single centre employs around 50 full-time employees and pays about $2 million USD each year in wages. Worldwide, CSL Plasma has 17,000+ employees. CSL Behring’s LEAD (Local Empowerment for Advocacy Development) Grant Program continues to support growing patient organisations working to improve awareness, access and care for people living with rare and complex diseases. In 2026, six organisations across Europe received grants of approximately €10,000 EUR each to advance locally led advocacy initiatives. This year’s recipients span Montenegro, Poland, Italy, Spain, the Czech Republic and Romania, representing conditions including hereditary angioedema, kidney disease, CIDP, alpha-1 antitrypsin deficiency, lymphoma and haemophilia. Their projects focus on priorities including earlier diagnosis, equitable access to care, patient education, data generation and holistic support – helping local organisations build capacity and capabilities to act on patient needs and drive meaningful change. advocacy Supporting Grassroots Patient CSL Plasma Donor Centres Support Local Economies 28 | CSL IMPACT REPORT 2026
A pandemic doesn’t wait for us to be ready. That’s exactly why agreements like this one matter. Gonzalo Pereira, CSL Seqirus Building Vaccine Preparedness Through Long-Term Partnerships In FY26, CSL Seqirus strengthened influenza preparedness across the Middle East, Latin America and Canada, using long-term partnerships to build more reliable vaccine supply and the capacity to respond quickly when a pandemic occurs. In Saudi Arabia, CSL Seqirus partnered with the Ministry of Health and Vaccine Industrial Company to establish local manufacturing of cell-based seasonal and pandemic influenza vaccines, with the future facility expected to become the first of its kind in the Kingdom and the largest in the Middle East. “Through this collaboration… [we aim] to establish the Kingdom as a regional leader in preventing seasonal influenza,” said Dr. Lorna Meldrum, CSL Seqirus. In Latin America and the Caribbean, a new agreement with the Pan American Health Organization (PAHO) reserves millions of doses of pandemic influenza vaccine for participating countries, while CSL Seqirus and regional partner Sinergium Biotech will build local vaccine production and distribution capability. In Canada, a new agreement will provide adjuvanted cell-based influenza vaccines if a pandemic is declared, manufactured at CSL Seqirus’ new Tullamarine facility in Australia. Together, these partnerships combine secure vaccine supply with local and regional capabilities, helping countries be better prepared to protect their populations when the next influenza pandemic strikes. As Gonzalo Pereira of CSL Seqirus said: “A pandemic doesn’t wait for us to be ready. That’s exactly why agreements like this one matter.” CSL IMPACT REPORT 2026 | 29
| Introduction | For Patients | For Science | For Society | Looking Ahead Bringing First Aid Education to More Communities CSL Seqirus has partnered with St John Ambulance in Queensland and New South Wales (NSW), Australia, to expand its First Aid in Schools program, providing education on bites and stings, with a focus on reaching regional, remote and First Nations communities. The partnership supports training, materials and travel to schools that often miss out on extracurricular programs. In Queensland, a 2025 pilot reached almost 500 students across four rural and remote schools, while further visits are extending into Far North Queensland and Cape York. In NSW, the program is building on a 2024–25 partnership that reached more than 10,000 students across 120 schools with bites and stings education, helping equip children with potentially lifesaving knowledge while improving access to first aid education. In 2026, CSL awarded eight Community Impact Awards to emerging leaders working across Australia’s health sector, in partnership with Melbourne Business School’s Centre for Social Purpose Organisations. The scholarships provide access to the three-month Emerging Social Purpose Leaders Program, equipping participants with practical skills in leadership, strategy, finance and stakeholder engagement. By investing in the people behind community health organisations, CSL is helping promising leaders strengthen their organisations and turn good ideas into lasting improvements in health. The 2026 recipients came from a range of organisations, including Murdoch Children’s Research Institute, Walter and Eliza Hall Institute of Medical Research (WEHI), UsherKids Australia, Hearing Australia, Patients Australia, The Fred Hollows Foundation and Rural Health Connect. Investing in the Next Generation of Health Leaders FY26 Sustainability Highlights CSL’s Healthier World strategy reflects the company’s commitment to improving lives, safeguarding public health and creating long-term shared value for patients, donors, employees, communities and the environment. In FY26, CSL continued to advance this strategy through its two core pillars – Healthier Communities and Healthier Environment – focusing on the areas where the company can have the greatest positive impact. Key improvements included: • Expanded access to lifesaving therapies through partnerships, including World Federation of Hemophilia (WFH) humanitarian aid support for people with bleeding disorders • Advanced FY30 access commitments, treating 1,993 people with bleeding disorders and supporting anaemia treatment for 207,000 people • Embedded patient insights into 100% of Phase II/III clinical trials, with flexible options to improve accessibility and reduce burden • Strengthened donor experience through a new framework and Voice of the Donor survey, achieving an 88.3% satisfaction score • Reduced Scope 1 and 2 Greenhouse Gas (GHG) emissions by 28% from the FY21 baseline • Sourced 100% of paper-based packaging used directly in manufacturing from certified sustainable forestry sources. 30 | CSL IMPACT REPORT 2026
RkJQdWJsaXNoZXIy MjE2NDg3